皮肤科多剂型产品立项评估数据

一种原料药开发多种制剂剂型在医药发达国家常见的做法，制剂开发集约化，节省原药开发投入，减少污染，节约营销资源投入，延长产品寿命。我们选择行业开发皮肤科剂型最多的3个品种倍他米松、糠酸莫米松、硝酸益康唑，采集全球范围内医药行业的产品市场信息、注册信息、专利技术信息以及法规信息，结合公司自身技术条件，为企业多剂型产品立项提供多维度情报信息支撑；同时借助大数据分析技术，对相关产品进行全面评估评分，挖掘高价值的目标产品，为制剂产品立项提供精准的线索，提升制剂产品立项工作的效能。皮肤科多剂型产品立项评估数据算法规则如下：市场规模大于等于20亿得1分，大于10亿小于20亿之间得0.5分，小于10亿不得分，分数填入右边的得分列。批文数量小于等于5个得1分，高于5个不得分，分数填入右边的得分列。公司营销领域内得1分，否则不得分，分数填入右边的得分列。是临床一线得0.5分，否则不得分，分数填入右边的得分列。原料药公司现有的得1分，否则不得分，分数填入右边的得分列。非专利产品得0.5分，专利未过期不得分，分数填入右边的得分列。产线投资规模低的得0.5分，高的不得分，分数填入右边的得分列。8项总和得分填入总分列，高分产品作为立项优选。

Developing multiple dosage forms for a single active pharmaceutical ingredient (API) is a common practice in developed pharmaceutical markets. Intensive dosage form development helps reduce API development costs, cut down environmental pollution, conserve marketing resources, and extend the product lifecycle.

We selected three APIs with the highest number of dermatological dosage forms developed in the global pharmaceutical industry: betamethasone, mometasone furoate, and econazole nitrate. We collected global pharmaceutical industry data covering product market information, registration filings, patent technology data, and regulatory information, and integrated these data with the company’s internal technical capabilities to provide multi-dimensional intelligence support for enterprises when initiating multi-dosage form product projects.

Meanwhile, by leveraging big data analysis technologies, we performed comprehensive evaluation and scoring of the relevant products, identified high-value target products, provided precise leads for dosage form product project initiation, and enhanced the efficiency of such project initiation work.

The algorithm rules for dermatological multi-dosage form product project initiation evaluation are as follows:
1. 1 point is awarded when the market size is ≥ 2 billion, 0.5 points when the market size is between 1 billion and 2 billion, and 0 points when the market size is <1 billion. Fill the corresponding score into the right-hand score column.
2. 1 point is awarded if the number of marketing approvals is ≤5, and 0 points if it exceeds 5. Fill the corresponding score into the right-hand score column.
3. 1 point is awarded if the product falls within the company’s marketing scope; otherwise, 0 points. Fill the corresponding score into the right-hand score column.
4. 0.5 points are awarded if the product is indicated for first-line clinical use; otherwise, 0 points. Fill the corresponding score into the right-hand score column.
5. 1 point is awarded if the company currently possesses the relevant API; otherwise, 0 points. Fill the corresponding score into the right-hand score column.
6. 0.5 points are awarded for generic products; 0 points are awarded if the product’s patent has not expired. Fill the corresponding score into the right-hand score column.
7. 0.5 points are awarded for small-scale production line investment, and 0 points for large-scale investment. Fill the corresponding score into the right-hand score column.

Sum the scores of the 8 evaluation items and enter the total score into the total score column; products with higher total scores will be prioritized for project initiation.

搜集汇总

数据集介绍

特点

该数据集为皮肤科多剂型产品立项评估数据，包含66条记录，涵盖三种原料药的多个评估维度评分，用于企业制剂产品立项决策支持。